Document is current
Any future updates will be listed below
-
Authors
Senesse, Pierre https://orcid.org/0000-0003-3542-2898
Deffrennes, Julie
Flori, Nicolas https://orcid.org/0000-0002-2983-7790
Janiszewski, Chloé https://orcid.org/0000-0002-3968-1021
Francioni, Laure
Thezenas, Simon https://orcid.org/0000-0003-2472-1219
Guerdoux, Estelle https://orcid.org/0000-0002-9608-0791
-
Funding
Funding for this research was provided by:
This study was supported by SIRIC Montpellier Cancer
This study was supported by SIRIC Montpellier Cancer (Grant INCa-DGOS-INSERM-ITMO Cancer_18004).
- License Information
-
More Information
Article History
Received: 13 February 2025
Revised: 21 October 2025
Accepted: 12 November 2025
First Online: 5 December 2025
Competing interests
: PS reports, with no competing interests with the submitted work, personal fees from Nestle Health Science Bbraun, Theradial, Mayoly Spindler, Novartis, Fresenius Kabi, Lilly France SAS, Nutricia Nutrition Clinique, Baxter SAS, AgirADom, Andros, HomeAir, Servier, NHC, BMS, Salgen SAS, Sanofi Aventis France, Kephren, Nestlé home care, Experf. NF reports personal fees, outside the submitted work, from Fresenius Kabi, Nestlé Health, BBraun, Viatis and TSC France. ST, CJ, LF and JD declare no competing interests. EG reports personal fees, without competing interests with the submitted work, from AstraZeneca, Nestlé Health, CancerConsult and Sanofi, outside the submitted work. She also reports grants without competing interests from the French National Cancer Institute (Grant INCa_15779 and Grant INCa-DGOS-Inserm_12553) and from the Ligue contre le Cancer (Grant SHS2018 and Grant 2024).
: The study was carried out in accordance with the Declaration of Helsinki and data were subject to an official declaration to the CNIL, the French Data Protection Authority: methodological reference MR-004. MR-004 is a form of patient informed consent for publication: no non-opposition was declared.
